Neurocrine biosciences-does not intend to provide formal ingrezza net product sales guidance for 2020 as tardive dyskinesia market continues to evolve

Neurocrine biosciences-does not intend to provide formal ingrezza net product sales guidance for 2020 as tardive dyskinesia market continues to evolve.given increase to year-end channel inventory, co anticipates it may lead to a reduction to channel inventory in q1 of 2020.during q1 2020, expects ingrezza net product sales to be impacted as a result of payer-related seasonal dynamics.during q1, expects ingrezza net product sales to be impacted also as a result of gross-to-net discount increases from payer.upon ind application acceptance by fda,expected in mid-2020, co will have 30 days to exercise option to license act-709478.
NBIX Ratings Summary
NBIX Quant Ranking